Continuity And Risk Mitigation Following Unexpected QPPV Resignation

Unexpected changes in pharmacovigilance leadership can create immediate compliance risk, particularly in regions with strict national requirements. When a local QPPV resigned without notice in South Africa, Prime Vigilance, a sister company of Ergormed Clinical Research, faced a critical gap in legal oversight, operational uncertainty, and increased exposure during potential inspections.

Rapid, structured intervention was required to maintain continuity and avoid regulatory escalation. Through a clearly defined escalation and governance model, interim local oversight was established while permanent arrangements were put in place. Clear communication, defined roles, and centralized coordination ensured ongoing pharmacovigilance activities continued without interruption. Regulatory obligations were maintained throughout the transition, operational stability was preserved, and confidence was reinforced during a high‑risk period.

This real‑world example demonstrates how proactive risk mitigation, strong escalation pathways, and structured transition support can protect compliance when key safety roles change unexpectedly. Read the full case study for practical insight into maintaining continuity during critical PV leadership transitions.